Company intelligence / Profile preview

Tupos Therapeutics

Oakland, CA, United Statespitchbook.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Tupos Therapeutics describes itself as a team of experienced drug hunters and industry leaders with a competitive pipeline focused on high-value targets using disruptive approaches. However, specific clinical results or detailed program information are not publicly disclosed as of early 2025. The company appears to be active and maintains good standing both in the US and Cayman Islands jurisdictions.

Industry: Biotech

Drug pipeline

1 asset

pexidartinib

Phase 1

Indications: Glioblastoma

Beyond the preview

Go deeper on Tupos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tupos Therapeutics.

Explore the full profile